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Abstract
The incidence of brain tumors in the elderly population has increased over the last few decades. Current treatment
includes surgery, radiotherapy and chemotherapy, but the optimal management of older patients with brain tumors
remains a matter of debate, since aggressive radiation treatments in this population may be associated with high risks
of neurological toxicity and deterioration of quality of life. For such patients, a careful clinical status assessment is
mandatory both for clinical decision making and for designing randomized trials to adequately evaluate the optimal
combination of radiotherapy and chemotherapy.
Several randomized studies have demonstrated the efficacy and safety of chemotherapy for patients with glioblastoma
or lymphoma; however, the use of radiotherapy given in association with chemotherapy or as salvage therapy remains
an effective treatment option associated with survival benefit. Stereotactic techniques are increasingly used for the
treatment of patients with brain metastases and benign tumors, including pituitary adenomas, meningiomas and
acoustic neuromas. Although no randomized trials have proven the superiority of SRS over other radiation techniques
in older patients with brain metastases or benign brain tumors, data extracted from recent randomized studies and
large retrospective series suggest that SRS is an effective approach in such patients associated with survival advantages
and toxicity profile similar to those observed in young adults. Future trials need to investigate the optimal radiation
techniques and dose/fractionation schedules in older patients with brain tumors with regard to clinical outcomes,
neurocognitive function, and quality of life.
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Introduction
Cancer is most frequently diagnosed among individuals
aged 65 years and older [1–3], and the number of older
patients with cancer will increase in the future as result of
increasing life expectancy of the population [4]. As for
other cancers, the incidence of either malignant or benign
brain tumors has been increasing in the elderly population
[4], representing an important aspect of public health.
Radiotherapy (RT) given alone or in combination with
systemic therapy is a cornerstone of the multidisciplinary
management of brain tumors and remains an attractive
option for older patients [5]. Advances in radiation plan-
ning and dose delivery have improved the safety and effi-
cacy of RT, although irradiation of brain tumors is
particularly challenging in older patients because of the
potential increased radiation-induced toxicity secondary
to comorbidities, impaired functional status and neuro-
cognitive function. In addition, older patients are under-
represented in randomized controlled clinical trials and
clinicians need to extrapolate data from studies done
with a much younger cohort. However, treating older
patients is not the same as treating patients in their 50s
or 60s. The clinical behavior of some tumors changes
with age. Some become more aggressive due to a high
prevalence of unfavorable genomic changes or resistance
to chemotherapy. For these reasons, treatment para-
digms for older patients with brain tumors are not well
defined.
The purpose of this review is to summarize the pub-
lished literature on the clinical outcomes of RT for the
most common brain tumors in the elderly population, and
to address important issues such as optimal radiation dose
and fractionation, combining RT with systemic therapy,
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quality of life and neurocognitive function after RT, and
future research priorities for this population.
Methods
A literature search was conducted in MEDLINE PubMed
evaluating older people with brain tumors. The search fo-
cused on randomized, prospective and retrospective stud-
ies published in English. The literature search was
performed using a combination of medical subject head-
ings (MeSH) (“brain tumors/radiotherapy” or “gliomas” or
“brain metastases” or “lymphomas” or “meningiomas” or
“pituitary adenomas” or “acoustic neuromas” or “older” or
“elderly”) and free text terms (“toxicity” or “radiosurgery”
or “fractionated stereotactic radiotherapy” or “chemother-
apy” or “chemoradiation”). Relevant prospective and retro-
spective studies published from 1990 to 2017 were
included. Studies published in languages other than Eng-
lish or not involving human subjects were not reviewed.
There was no definitive age cutoff used for defining older
patients. A total of 312 potentially relevant studies were
identified, including 47 prospective/randomized studies
and 265 retrospective studies. The results of the literature
research were used and included if appropriate.
General aspects of radiation treatment in older
patients
The aging process is characterized by a decrease in the
function of various organ systems, as well functional,
cognitive, emotional, and socioeconomic changes [6, 7].
It is also associated with an increased incidence of co-
morbidities and geriatric syndromes. Common geriatric
syndromes include delirium, gait imbalance, malnutrition,
and incontinence that can complicate treatments and may
increase patient morbidity [8]. When considering the ap-
propriate therapy for an older patient with cancer, a base-
line assessment of these multiple factors can be useful to
determine if a patient is fit or frail [9–11]. Fit older adults
have few comorbidities, no functional deficits, any or few
geriatric syndromes, and generally may be considered ap-
propriate for the same therapies used in younger adults.
In contrast, frail patients have difficulty of maintaining
functional independence, multiple chronic conditions and
geriatric syndromes that make them more vulnerable to
toxicities from therapy. In order to help cancer specialists
to determine the best treatment for their older patients,
the U.S. National Comprehensive Cancer Network, the
European Society of Breast Cancer Specialists, the Inter-
national Society of Geriatric Oncology (SIOG), and the
European Organization for the Research and Treatment
of Cancer have recommended the use of a comprehensive
geriatric assessment (GA) in older patients with cancer
[12–16].
A GA is a multidisciplinary diagnostic process that
evaluates the risk of adverse outcomes of death and
functional decline in older cancer patients. A compre-
hensive GA includes the evaluation of functional status,
cognitive function, nutritional status, comorbidities,
polipharmacy, and socioeconomic status in every older
cancer patient with the aim of developing the optimal
treatment plan. Several systematic reviews have showed
that GA is beneficial in improving outcome and redu-
cing the risk of adverse outcomes [17–19].
Several instruments have been reported in the litera-
ture to assess the different domains of GA [6, 20, 21–37]
(Table 1). Functional assessment instruments, such as
Eastern Cooperative Oncology Group (ECOG) perform-
ance status scale and the Karnofsky Performance Scale
(KPS) are widely used in oncology setting. Additional in-
struments to assess the functional status that capture
additional information not obtained by accessing per-
formance status alone include activities of daily living
(ADLs) and instrumental activities of daily living
(IADLs) [6, 22, 23]. ADLs are a measure of six basic self-
care skills: bathing, dressing, toileting, continence, tranfer-
ring, and feeding [6]; IADLs refers to 8 functions that are
needed to live independent and include travelling, shop-
ping, using the phone, preparing meals, laundry, doing
house-work, taking medicine and managing money [22].
Cognitive function may be assessed by several instruments,
including the Mini-Mental State Examination (MMSE)
[24], the Montreal Cognitive Assessment (MoCA) [25], the
Blessed Orientation Memory Concentration [26], and the
Clock drawing test [27]. Comorbidities that can have sig-
nificant impact on treatment tolerance and outcome are
usually measured by standardized instruments as the Charl-
son Comorbidity Index (CGI) [29] and the Cumulative Ill-
ness Rating Scale-Geriatrics (CIRS-G) [30]. Additional
validated tools included in GA explore depression and psy-
chological distress (Geriatric depression scale [31], hospital-
ized anxiety and depression scale [32]; patient health
questionnaire [33, 34], nutrition status (body mass index;
Mini Nutritional Assessment [35], and socioeconomic sta-
tus [38, 39]. Currently, no specific tools are usually recom-
mended and their choice depends both on the resource
available at different cancer centers and patient population.
A full comprehensive GA takes an average between 30
and 120 min and this may limit its use in all older can-
cer patients in a busy clinical practice. Thus, several
screening tests have been developed and implemented in
daily practice. The most widely used screening instru-
ments are the G8 [40], the abbreviated comprehensive
geriatric assessment (aCGA) [41], the Groningen frailty
indicator (GFI) [42], and the vulnerable elders survey-13
(VES-13) [43]. In general, those older adults who scored
above the cutoff of the screening instruments should re-
ceive a complete GA.
In summary, GA is a critical process that can help to
identify fit, vulnerable, or frail older cancer patients. Its
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use should be implemented in clinical practice to help
oncologists to guide cancer treatment decision-making
and improve function and quality of life of older pa-
tients. GA models need to be incorporated in future
clinical trials in order to validate their effectiveness in
older patients with brain cancer treated with RT and/or
chemotherapy.
Malignant gliomas
Glioblastoma (GBM) is the most common primary brain
tumor in adults, with an incidence rate among elderly
patients of 70 years and older of 17.5 per 100,000
person-years, and a relative risk of 3–4 times compared
with young adults [4].
RT is frequently used in older patients with GBM. Its
superiority over supportive care alone has been demon-
strated in a French multi-institutional randomized trial
of 85 elderly patients aged 70 years and older [44]. The
median survival and progression-free survival times were
29.1 and 14.9 weeks in patients treated with RT (50 Gy
given in daily fractions of 1.8 Gy) plus supportive care,
and 16.9 and 5.4 weeks for those treated with supportive
care alone (p = 0.002), respectively. As compared with
supportive care, RT did not cause further deterioration
in KPS, quality of life and cognitive function.
The efficacy of either radical RT or abbreviated
courses of RT has been evaluated in randomized and
prospective studies [45–54] (Table 2). Roa et al. [50]
have conducted a trial of patients aged 60 years and
older with newly diagnosed GBM randomized to receive
standard RT (60 Gy in 30 daily fractions) or an abbrevi-
ated course of RT (40 Gy in 15 daily fractions) after sur-
gery. The median survival time and 6-month survival
rates were similar between groups, being 5.1 months
and 44.7% after standard RT and 5.6 months and 41.7%
after short-term RT (p = 0.57), respectively. In another
study of 291 patients older than 60 years with newly di-
agnosed GBM (Nordic study) randomly assigned to re-
ceive RT or chemotherapy with temozolomide (TMZ),
RT was given as radical RT or hypofractionated RT (34
Gy given in 3.4 Gy fractions over 2 weeks). Median over-
all survival was significantly longer for patients who re-
ceived TMZ than those who received standard RT (8.3
months vs 6.0 months, hazard ratio 0.7, 95% CI 0.52–
0.93, p = 0.01), but not significantly better than those
treated with hypofractionated RT (7.5 months, HR 0.82,
95% CI 0.63–1.06, p = 0.12); for patients older than 70
years, median overall survival was better with hypofrac-
tionated RT than with standard RT (7.0 months vs 5.2
months, p = 0.02).
In a recent Canadian study of 98 frail and/or elderly
patients with GBM randomized to receive two different
hypofractionated radiation schedules, Roa et al. [54] ob-
served median overall survival times of 7.9 months (95%
CI, 6.3 to 9.6 months) in patients who received 25 Gy in
five daily fractions and 6.4 months (95% CI, 5.1 to 7.6
months) in those receiving 40 Gy in 15 daily fractions
over 3 weeks (p = 0.9), with a similar median
progression-free survival times of 4.2 months in both
groups. With a median follow-up time of 6.3 months,
the quality of life between groups at 4 weeks and 8
weeks after treatment was not different.
The main concern about the use of a radical course of
RT in older patients with GBM is the potential high inci-
dence of radiation-induced neurological toxicity and de-
terioration of quality of life. Roa et al. [50] reported no
significant differences in KPS scores over time between
standard RT and hypofractionated RT, although 49% of
patients treated with standard RT required an increase
in corticosteroid dosage as compared with 23% of pa-
tients who received short-term RT (p = 0.02). Similarly,
in the Nordic study no significant differences were
observed in physical, role, emotional, social, and cogni-
tive functioning, and global health status between
patients receiving standard RT or hypofractionated RT
[52]. However, data should be interpreted with caution
Table 1 Domains of geriatric assessment and examples of
instruments used for each domain
Domain Commonly used instruments
Physical function/falls [20, 21] Timed up and go [20]
Self-reported number of falls
Short Physical performance battery [21]
Grip strenght
Functional status [6, 22] Activities of daily living (ADLs)
Instrumental activities of daily living
(IADLs)
Cognitive function [23–28] Mini Mental State Examination
Montreal cognitive Assessment
Blessed Orientation Memory
Concentration Test
Clock Drawing Test
Memorial Delirium Assessment Scale
Comorbidities [29, 30] Charlson Comorbidity Index (CGI)
Cumulative Illness Rating Scale-
Geriatrics (CIRS-G)
Depression/Psycological status
[31, 34]
Geriatric depression scale
hospitalized anxiety and depression
scale
patient health questionnaire
Nutrion [35] Body mass index
Mini Nutritional Assessment Short Form
Polipharmacy [36, 37] Medication Appropriateness index
STOPP/START Criteria
Socioeconomic status [38, 39] Lubben Social Network Scale
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because of the low number of completed questionnaires.
In a prospective series of 43 elderly patients aged 70
years and older with GBM who received hypofractio-
nated RT given at the dose of 30 Gy in 6 fractions over 2
weeks followed by adjuvant TMZ, no negative effects of
treatment on KPS and health-related quality of life
scores were observed [55]. Analysis of the European Or-
ganisation for Research and Treatment of Cancer
(EORTC) quality of life (QOL) C-30 questionnaires
showed that global health status and several functioning
scales, including physical, role, emotional, social, and
cognitive functioning, did not deteriorate in the majority
of patients until tumor progression. An improved func-
tional status has been reported by others using other
hypofractionated schedules [45, 48].
The use of chemotherapy as an alternative to RT in
older patients with malignant gliomas has been ad-
dressed in a few prospective and randomized studies
[49, 51–53] (Table 2). In the German Neuro-oncology
Working Group (NOA) phase 3 trial (NOA-08), 373 pa-
tients older than 65 years with histologically confirmed
anaplastic astrocytoma or GBM, and a KPS score ≥ 60,
were randomly assigned to receive dose-dense TMZ (1
week on, 1 week off schedule, 100 mg/m2 given on days
1–7) or standard RT [53]. Median event-free survival
time was 3.3 months for patients treated with TMZ and
4.7 months for those treated with standard RT (hazard
ratio 1.15, 95% CI 0.92–1.43, p = 0.03), respectively. Me-
dian survival was 8.6 months for patients treated with
TMZ and 9.6 months for those treated with standard RT
(hazard ratio 1.09, 95% CI 0.84–1.42, p = 0.03), respect-
ively, indicating that chemotherapy was non-inferior to
standard RT. Analysis of health-related quality of life
scales showed no significant differences between groups;
however, grade 2–4 adverse events were more frequent
in the TMZ group. A striking finding of the study was
the predictive role of O6-methylguanin-DNA-methyl-
transferase (MGMT) promoter methylation status on
survival outcomes. MGMT promoter methylation was
associated with longer survival (median 11.9 months vs
8.2 months; hazard ratio 0.62, 95% CI 0.42–0.91, p =
0.014) and longer event-free survival (median 5.7
months vs 3.5 months; hazard ratio 0.5, CI 0.36–0.68, p
< 0.001) than unmethylated status. The presence of
MGMT promoter methylation was associated with bet-
ter event-free survival time only in patients who received
TMZ, but not in patients who received RT, whereas the
opposite was true for patients with unmethylated tumor.
In the Nordic study [52], no survival differences were
observed amongst patients aged 60–70 years who re-
ceived standard RT, hypofractionated RT or TMZ; how-
ever, for patients older than 70 years median overall
survival was better with TMZ and hypofractionated RT
than with standard RT (9.0 and 7.0 months vs 5.2
months, p < 0.0001 and p = 0.02). Data for health-related
quality of life, including cognitive functioning and global
health status, were generally better in patients who re-
ceived TMZ than in those who received RT; however,
because of the low number of completed questionnaires
results need to be interpreted with caution. As for the
NOA-8 trial, the study confirmed the predictive value of
MGMT promoter methylation. Amongst patients treated
with TMZ, median overall survival was 9.7 months for
those with methylated tumors and 6.8 for those with
unmethylated tumors (p = 0.02). In contrast, MGMT
methylation status did not affect survival in patients
treated with RT (8.2 months in methylated vs 7.0
months in unmethylated tumors, p = 0.81).
The use of standard or hypofractionated RT in com-
bination with adjuvant and/or concomitant TMZ, which
is the standard treatment in adult patients with GBM,
has been reported in several studies [56–67]; selected
prospective series are showed in Table 3. In a small pro-
spective series of 32 patients aged 70 years and older
treated with radical RT in combination with adjuvant
and concomitant TMZ at University of Rome Sapienza,
Sant’Andrea Hospital, the reported median overall sur-
vival and 1-year survival rates were 10.6 months and
37%, respectively [58]. Grade 3 or 4 hematologic toxic
effects occurred in 24% of patients. Brandes et al. [59]
have reported the results of 58 patients aged 65 years
and older who received standard chemoradiation for a
newly diagnosed GBM. The overall median survival was
13.7 months, being significantly better in patients with
methylated tumors (p = 0.05). Overall survival rates were
83 and 69% for patients with methylated tumors and 56
and 38% for those with unmethylated tumors at 2 and 3
years, respectively. Radiation Therapy Oncology Group
(RTOG) Grade 2 and grade 3 mental status deterioration
were detected in 31 and 25% of patients, respectively.
The use of hypofractionated RT using a dose of 40
Gy given in 15 daily fractions in association with con-
comitant and adjuvant TMZ has been evaluated in a
phase 2 trial in 70 patients aged 70 years and older
with newly diagnosed GBM [63]. The median overall
survival time and 1-year survival rate were 12.4
months and 58%; respective progression-free survivals
were 6 months and 20%. MGMT promoter methyla-
tion was the most significant favorable prognostic fac-
tor for survival. The 1-year and 2-year survival rates
were 81 and 20% in MGMT methylated tumors, and
32 and 0% in MGMT unmethylated tumors, respect-
ively (p = 0.0001). The treatment was well tolerated
and was consistently associated with improvement or
stability in most of health-related quality of life scales
[66]. Global health, social functioning, and cognitive
functioning scores improved significantly between
baseline and 6-month follow-up.
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Results of the intergroup EORTC 26062-22061-NCIC
Clinical Trials Group (NCI-CTG) CE6 randomized trial
comparing the same regimen of hypofractionated RT (40
Gy in 15 fractions) to hypofractionated RT plus con-
comitant and adjuvant TMZ in 562 patients older than
65 years old with newly diagnosed GBM have been re-
cently published [67]. RT plus TMZ significantly im-
proved overall survival time (9.3 vs 7.6 months, p <
0.0001) and progression-free survival (5.3 vs 3.9 months,
p < 0.0001) over RT alone. MGMT methylation status
was the strongest prognostic factor for survival. Amongs
165 patients with methylated MGMT status, overall sur-
vival was 13.5 months and 7.7 months in RT + TMZ
group and RT group, respectively (p = 0.0001); in
unmethylated patients, respective overall survival was
10.0 months and 7.9 months (p = 0.055). Analyses of
quality of life assessed by the EORTC Quality of Life
Questionnaire–Core 30 (QLQ-C30) and the EORTC
brain module (QLQ-BN20) showed that nausea and con-
stipation were worse during chemoradiotherapy than
during RT alone, but changes in the scores of all other
symptom and function domains were similar in the two
groups. In a large retrospective study of 243 older pa-
tients with GBM of 65 years or older who received
standard RT or short-course RT plus concomitant and
adjuvant temozolomide, the two treatments resulted in
similar survival benefits of about 12 months, although
short-course RT was associated with lower risks of
neurological deterioration.
In summary, RT remains an essential treatment op-
tions in older patients with newly diagnosed GBM. An
abbreviated course of RT may provide survival benefits
similar to those reported with radical RT, maintaining an
acceptable quality of life and potentially avoiding the
long-term toxicity of more aggressive treatments. TMZ
may represent a reasonable treatment option in older
patients with MGMT promoter methylated tumors that
is associated with survival benefit similar or even better
than that reported with standard RT. In contrast, TMZ
produces no benefit in patients with unmethylated tu-
mors, and its use as initial treatment is not recom-
mended. Recent studies have clearly demonstrated that
the addition of concomitant and adjuvant TMZ to an
abbreviated course of RT is a safe and more effective
treatment for older patients with GBM as compared
with RT alone, suggesting that chemoradiation can be
considered the standard therapeutic option for this
population.
Primary central nervous system lymphoma
The incidence of primary central nervous system lymph-
oma (PCNSL), a lymphoproliferative disorder that may
affect the brain, eyes, spinal cord or leptomeninges in
absence of systemic involvement, is 3–4% of all primary
brain tumors [68]. PCNSL has a predilection for the eld-
erly population, with a median age at diagnosis of 55
years and a peak incidence in the sixth and seventh de-
cades of life [69, 70]. Whole brain radiation therapy
(WBRT) was historically the modality of choice to treat
PCNSL until the early 1990s. PCNSL responds relatively
quickly to RT, and the complete disappearance of enhan-
cing tumor masses is frequently observed. However,
local recurrence and intracranial progression at distant
brain sites occurs within few months, and the reported
survival outcome of patients treated by radiation alone is
relatively poor [71, 72].
A combination of chemotherapy and WBRT has been
evaluated in several studies in order to improve the dis-
appointing survival observed after WBRT alone. High-
dose methotrexate (hd-MTX) is currently the corner-
stone of treatment of PCNSL with or without consolida-
tion WBRT [73–75]; RT is typically given at 36–45 Gy
in 1.6–1.8 Gy/fraction, with the aim to delay progression
and improve survival. The superiority of combination of
hd-MTX and radiation over radiation alone has been ob-
served in several studies [76–78], even if a formal com-
parison has never been carried out; however, combined
modality therapy appears to be associated with an in-
creased risk of neurotoxicity, and its use has been ques-
tioned particularly in older patients [79, 80]. In a study
of 31 patients with PCNSL treated with hd-MTX,
WBRT, and high-dose cytarabine, Abrey et al. [79] ob-
served an incidence of severe late treatment-related tox-
icity in nearly one third of patients, with those of 60
years and older of age at higher risk (p < 0.0001).
The use of chemotherapy alone for older patients
with PCNSL, with the omission of consolidation RT,
the standard approach until recent years, has there-
fore been tested in prospective studies over the past 2
decades [81–88]. In the German G-PCNSL-SG-1 ran-
domized trial [81], 318 patients with a median age of
63 years who received primary treatment with hd-
MTX-containing chemotherapy were then randomized
to receive WBRT or not. The median overall survival
was 32.4 months among patients that received WBRT,
and 37.1 months in patients treated with chemother-
apy alone (p = 0.71). Although the study failed to
show the non-inferiority of omitting the WBRT, there
were strong indications that this was the case for
older patients [88] (Table 4). In addition, older pa-
tients or patients with a poor performance status who
received WBRT experienced a higher incidence of se-
vere neurotoxicity. Survival times of 14 to 36 months
have been reported in other published studies with
the use of MTX given in combination with other
systemic agents including procarbazine, vincristine,
cytarabine, temozolomide, rituximab, and lomustine
[82–87] (Table 4).
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While these studies indicate that WBRT can be with-
held and a radiological surveillance policy adopted for
older patients who achieve complete remission, RT
should be considered for those with residual disease
after chemotherapy or in patients whose medical comor-
bidity precludes chemotherapy. An alternative approach
to standard WBRT in older patients is represented by
the use of low-dose consolidative RT, in the effort of
maintaining the potential benefit of radiation while lim-
iting the risk of neurotoxicity [89, 90]. In a phase II
study conducted at Memorial Sloan Kettering, 52 pa-
tients were treated with WBRT, using 23.4 Gy in 1.8 Gy
fractions after hd-MTX, rituximab, vincristine and pro-
carbazine, and 2 cycles of consolidative high-dose Ara-C.
Results, with rigorous neurocognitive testing, showed
very good disease control (35% of patients relapsed) with
minimal neurotoxicity [89]. In another retrospective
series of 33 patients with PCNSL who received consoli-
dation WBRT after HD-MTX, Ferreri et al. [90] ob-
served no significant difference in disease control
between patients who received WBRT doses ≥40 Gy or
doses of 30–36 Gy (relapse rate, 46 vs. 30%; 5-year
failure-free survival, 51 vs. 50%; p = 0.26). Currently, the
randomized phase II study RTOG 1114 is exploring the
effects of rituximab, methotrexate, procarbazine, vincris-
tine and cytarabine with and without low-Dose WBRT
for PCNSL. A few series suggest that the use of partial
brain irradiation may be considered in patients with a
single tumor [72, 91]; however, in current clinical prac-
tice WBRT remains the standard technical approach (in-
cluding optic nerves and with a lower limit at C1-C2).
In summary, most studies support the use of
chemotherapy-only treatments for elderly patients given
the high risks of neurotoxicity associated with radiother-
apy. Despite the concerns about the detrimental neuro-
cognitive effects of WBRT in the elderly population with
PCNSL, it should not be forgotten that WBRT maintains
an important palliative role in patients achieving partial
response, or who are not candidate for hd-MTX based
chemotherapy. Patients unfit for a protracted course of
RT can be offered low-dose WBRT or a course of hypo-
fractionated RT (e.g. 30 Gy/10 fractions). For very eld-
erly patients who are too confused to undergo RT safely,
palliative management with steroids alone may be the
preferred option.
Brain metastases
Brain metastases occur in up to 40% of patients with
cancer, and treatment options include supportive care,
surgery and RT. WBRT has classically been the standard
treatment for patients with brain metastases with a re-
ported median survival of 3–6 months [92]. Older age
has been reported as an unfavorable prognostic factor
for survival [93–95]; using recursive portioning analysis
(RPA) the Radiation Therapy Oncology Group (RTOG)
has analyzed 1200 patients treated with WBRT enrolled
in three consecutive RTOG trials conducted between
1979 and 1993, describing three prognostic classes de-
fined by age, KPS, and disease status [93]. The reported
survival for patients of 65 years and over (RPA class II
and III) was less than 5 months, with the worst outcome
observed in patients with a KPS < 70 (RPA class III). In
addition, the use of WBRT has been associated with the
risk of neurocognitive deterioration [96–99], and this is
of concern especially in older patients.
SRS has been increasingly used in the initial manage-
ment of patients with brain metastases. The rationale for
this approach is to achieve local control while avoiding
the risk of the detrimental neurocognitive effects of
WBRT. Although no prospective trials have been specif-
ically addressed the clinical outcomes of SRS in older
patients with brain metastases, data extracted from three
randomized studies comparing the use of WBRT plus
SRS versus SRS alone in patients of all ages show no sig-
nificant survival differences between younger and older
patients [99–103]. Aoyama et al. [100] reported 132 pa-
tients with 1 to 4 brain metastases randomized to re-
ceive WBRT plus SRS or SRS alone. The use of SRS
alone resulted in a similar survival and risk of neurologic
death as compared with WBRT plus SRS, with no sig-
nificant differences between patients < 65 years and
those ≥ 65 years. In another randomized trial of 213 pa-
tients with 1 to 3 brain metastases treated with SRS or
SRS plus WBRT between February 2002 and December
2013, Brown et al. [103] reported similar median overall
survival times of 7.4 months for patients who received
SRS plus WBRT and 10.4 months for those receiving
SRS alone (hazard ratio 1.02; 95% CI, 0.75–1.38; p = 0.9).
Analysis by age, extracranial disease status, and number
of brain metastases revealed no survival benefit in any
group. Similar overall survival times in the range of 6 to
12 months without a clinically significant neurocognitive
decline have been reported in few retrospective series of
older patients with brain metastases treated with SRS
[104–106].
Interestingly, the recently proposed diagnosis-specific
graded prognostic assessment (DS-GPA) score offers dif-
ferent patterns of diagnosis-specific prognostic factors
and seems more appropriate than RPA Classes in pre-
dicting the outcome that can be expected from the vari-
ous treatment options in the elderly population [107].
According to the DS-GPA scores, number of metastases
and/or KPS, but not age, are significant prognostic fac-
tors for survival in several types of cancer, including
breast cancer, renal cell cancer, gastrointestinal cancer,
and melanoma.
The main reason for using SRS alone is that WBRT
may be associated with a decline in quality of life [108,
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109] and neurocognitive function [98, 99, 101, 103]. In
58 patients with 1 to 3 metastases randomly assigned to
receive WBRT plus SRS or SRS alone, Chang et al. [101]
observed that patients treated with SRS plus WBRT
were significantly more likely to show a decline in learn-
ing and memory function at 4 months than patients
assigned to receive SRS alone. In another randomized
trial comparing the cognitive function in patients treated
with SRS alone or SRS plus WBRT, Brown et al. [103]
observed significantly less cognitive deterioration at 3
months after SRS alone as compared with SRS plus
WBRT (difference, −28.2%; 90%CI, −41.9% to −14.4%; p
< .001). In addition, overall quality of life was higher at 3
months after SRS alone (mean change from baseline,
−0.1 vs −12.0 points; mean difference, 11.9; 95%CI, 4.8–
19.0 points; p = 0.001).
Two recent studies have evaluated the protective ef-
fects of memantine and IMRT planning for hippocam-
pus sparing on cognitive function among patients
receiving WBRT for brain metastases [110, 111]. In the
phase III RTOG 0614, 508 adult patients were ran-
domized to receive WBRT with placebo or memantine
(20 mg/d) for 24 weeks [110]. The study failed to dem-
onstrate a significant less decline in delayed recall in the
memantine arm (p = 0.059), possibly due to the low
number of analyzable patients at 24 weeks; however, pa-
tients receiving memantine had better cognitive function
over time as compared with those receiving WBRT
alone; specifically, memantine delayed time to cognitive
decline and reduced the rate of decline in memory, ex-
ecutive function, and processing speed. In the RTOG
0933 single-arm phase II study of 113 patients who re-
ceived WBRT with hippocampal sparing for brain me-
tastases, results of cognitive function and health-related
QOL, assessed by the Hopkins Verbal Learning Test–
Revised Delayed Recall and the Functional Assessment
of Cancer Therapy–Brain subscale (FACT-BR), respect-
ively, were compared with those observed in prespecified
historical control of patients treated with standard
WBRT (30 Gy in 10 fractions) [111]. Among 42 patients
who were analyzable at 4 months, mean relative decline
in delayed recall from baseline to 4 months was 7.0%
(95% CI, −4.7 to 18.7%), being significantly lower than
historical control (p < .001); no decline in QOL scores
was observed. Based on these results, a randomized
phase III trial exploring the use of memantine and
WBRT with or without hippocampal avoidance in pa-
tients with brain metastases has been activated (https://
clinicaltrials.gov/ct2/show/NCT02360215).
In summary, data extracted from randomized trials
and retrospective studies suggest that SRS is a reason-
able approach to older patients with a limited number of
brain metastases with both survival benefit and toxicity
profile similar to those observed in young adults. Future
randomized studies need to investigate the advantages of
such approach in the elderly in terms of survival and
quality of life over other treatment options.
Benign tumors
Incidence of benign tumors, including meningiomas,
acoustic neuromas and pituitary adenomas increases
with age [4]. Meningiomas constitute the most common
non-glial brain tumor histological type and accounts for
approximately 12–20% of all primary intracranial tu-
mors. The risk for developing meningioma grows with
age and increases dramatically after the age of 65, reach-
ing a peak at the seventh decade of life. An incidence of
8.5 per 100,000 persons per year has been recorded
among elderly people, which is significantly higher com-
pared to 1–2.8 cases per 100,000 persons per year esti-
mated for the general population [4, 112]. While surgery
has traditionally been the mainstay of treatment of
symptomatic and fast growing tumors in all age groups,
RT is frequently employed after incomplete resection,
recurrent tumors, or for patients at risk of severe mor-
bidity with a reported excellent local control and low
toxicity [113].
In general, large published series including patients of
all ages with a meningioma treated with either SRS or
fractionated stereotactic RT (FSRT) reported no differ-
ences in local control and treatment-related toxicity be-
tween younger and older patients [114–121]. Two
retrospective studies have assessed the outcome of FSRT
in older patients with meningiomas [122, 123]. In a
series of 121 patients treated with FSRT (55.8 Gy in 1.8
Gy fractions), hypofractionated stereotactic RT (25-35Gy
in 5–7 fractions) or SRS (15–18 Gy), Fokas et al. [122]
reported a similar local control of about 95% at 5 years,
with no new neurologic deficits, radiation necrosis or
radiation-induced secondary malignancies. In another
study of 100 patients aged 65 or older (median age 71
years) treated with FSRT (56.5 Gy), hypofractionated
stereotactic RT (36.3 Gy in 5–7 fractions) or single-fraction
SRS (17.6 Gy), Kaul et al. [123] observed a 5-year local con-
trol of 91.1%, with no grade 2 or 3 neurological toxicity. No
study have specifically addressed the outcome of RT in
older patients with either secreting or nonsecreting pituit-
ary adenomas, and acoustic neuromas; however, data re-
ported in large retrospective studies and systematic reviews
show similar local control and toxicity between young and
older patients after either SRS or FSRT [124–142]. Single-
fractions doses of 13–16 Gy and 20–28 Gy are usually
employed for non-functioning and secreting pituitary aden-
omas [124, 125, 129–134], respectively, and of 12–14 Gy
for acoustic neuromas [135, 137, 139–142]. Hypofractio-
nated RT and FSRT using doses of 21–25 Gy in 3–5 frac-
tions and 45–54 Gy in 25–30 daily fractions of 1.8 Gy,
respectively, are frequently employed for large tumors
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involving the optic pathway or compressing the brainstem
[126–128, 133–136, 138].
Conclusions
RT remains an effective treatment in elderly patients with
brain tumors. For large malignant gliomas, randomized
studies comparing standard RT versus hypofractionated RT
show similar survival benefit, although short-term courses
of RT are associated with a better safety profile. Decisions
regarding the choice between RT and TMZ chemotherapy
should be based on the assessment of MGMT promoter
methylation status. Patients with methylated tumors receive
the most significant survival benefit from treatment with
TMZ; by contrast, chemotherapy produces no benefit in
patients with unmethylated tumors, suggesting that RT is a
better option in these patients. An abbreviated course of
RT plus TMZ has recently emerged as a safe treatment as-
sociated with improved survival over RT alone.
SRS alone represents a feasible approach for older pa-
tients with a limited number of brain metastases, with
reported survival and risk of neurologic death similar to
those observed for younger patients. This approach al-
lows omitting or the delaying the use of WBRT in older
patients, who are usually more sensitive to the negative
impact of cranial irradiation on neurocognitive function
and quality of life. Similarly, the use of stereotactic tech-
niques, either SRS or FSRT, has permitted the delivery
of safe radiation doses in older patients with skull base
tumors, leading to excellent long-term tumor control
with minimal side effects and preservation of quality of
life. The choice of stereotactic technique is usually based
on size and location of tumor. In clinical practice, SRS is
recommended for small-to-moderate tumors (<2.5-3
cm) that do not involve radiosensitive structures, such
as optic chiasm and brainstem; hypofractionated SRT or
FSRT would be a better treatment option when a single-
fraction dose carries an unacceptable risk of toxicity.
Future studies need to evaluate the impact of different
radiation techniques on survival, neurocognitive outcome
and quality of life in older patients with brain tumors, as
well their comparison with regimens incorporating RT
and/or chemotherapy. A rigorous assessment of tolerance
of different brain structures, including optic chiasm, cra-
nial nerves, brainstem, and hippocampus to different radi-
ation dose/fractionation schedules in older population is a
research priority for radiation oncologists.
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